Acta Medica International

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 4  |  Issue : 1  |  Page : 56--61

Heme iron polypeptide (proferrin®-ES) versus iron saccharate complex (ferrosac) for treatment of iron deficiency anemia during pregnancy


Ibrahim A Abdelazim1, Mohannad Abu-Faza3, Assem A. M Elbiaa3, Hossam S Othman3, Dareen A Alsharif3, Walid Farok Elsawah2 
1 Department of Obstetrics and Gynecology, Ain Shams University, Egypt; Department of Obstetrics and Gynecology, Ahmadi Hospital, Kuwait
2 Department of Critical Care and Emergency, Ahmadi Hospital, Kuwait

Correspondence Address:
Ibrahim A Abdelazim
Professor and Consultant of Obstetrics and Gynecology, Ain Shams University, Egypt and Ahmadi Hospital, Kuwait Oil Company (KOC), Ahmadi

Objectives: Anemia is one of the world's leading causes of considerable perinatal morbidity and mortality. This study designed to compare the efficacy and safety of Heme iron polypeptide (Proferrin®-ES) versus iron saccharate complex (Ferrosac) in treatment of iron deficiency anemia during pregnancy. Methods: Two hundred and sixty (260) pregnant women with hemoglobin level below 10 gm/dl due to iron deficiency anemia were included in this study and randomized to receive either; intravenous Iron Saccharate (IV group) or oral Proferrin®-ES (PO group) for correction of iron deficiency anemia during pregnancy. Treatment efficacy checked by comparing pre-treatment values of hemoglobin, serum ferritin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and reticulocytes count by the 3-months` post-treatment values. Results: The 3-months` post-treatment hemoglobin level increased compared to the pre-treatment level without any significant difference between the two studied groups (from 8.5 ± 3.5 to 11.3 ± 1.3 gm/dl in PO group and from 8.7 ± 2.5 to 11.7 ± 0.9 gm/dl in IV group). In addition; the 3-months` post-treatment ferritin level, increased compared to the pre-treatment level without any significant difference between the two studied groups (from 19.4 ± 4.9 to 118.8 ± 7.1 ug/l in PO group and from 15.3 ± 5.6 to 122.3 ± 6.4 ug/l in IV group). 1.6% (2/124) of the studied women developed gastrointestinal intolerance and upset with oral Proferrin®-ES (insignificant difference and excluded from the study) and no other side effects recorded with oral Proferrin®-ES. Conclusion: HIP (Proferrin®-ES) is an effective, safe, well tolerable oral iron preparation as well as intravenous iron saccharate complex for treatment of iron deficiency during pregnancy; it increases the hemoglobin and replaces the depleted iron store.


How to cite this article:
Abdelazim IA, Abu-Faza M, Elbiaa AA, Othman HS, Alsharif DA, Elsawah WF. Heme iron polypeptide (proferrin®-ES) versus iron saccharate complex (ferrosac) for treatment of iron deficiency anemia during pregnancy.Acta Med Int 2017;4:56-61


How to cite this URL:
Abdelazim IA, Abu-Faza M, Elbiaa AA, Othman HS, Alsharif DA, Elsawah WF. Heme iron polypeptide (proferrin®-ES) versus iron saccharate complex (ferrosac) for treatment of iron deficiency anemia during pregnancy. Acta Med Int [serial online] 2017 [cited 2021 Dec 8 ];4:56-61
Available from: https://www.actamedicainternational.com/article.asp?issn=2349-0578;year=2017;volume=4;issue=1;spage=56;epage=61;aulast=Abdelazim;type=0